Abstract | Here, we discuss three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects. RNA interference and antisense oligonucleotides downregulate gene expression by inducing enzyme-dependent degradation of targeted mRNA. Steric-blocking oligonucleotides block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this mechanism, steric-blocking oligonucleotides can redirect alternative splicing, repair defective RNA, restore protein production or downregulate gene expression. Moreover, they can be extensively chemically modified to acquire more drug-like properties. The ability of RNA-blocking oligonucleotides to restore gene function makes them best suited for the treatment of genetic disorders. Positive results from clinical trials for the treatment of Duchenne muscular dystrophy show that this technology is close to achieving its clinical potential.
Most currently marketed drugs are small molecules that target proteins such as enzymes and receptors, which represent a considerably small subset of total cellular proteins. By contrast, oligonucleotides are macro molecules that target pre-mRNA and mRNA -the carriers of genetic information before it is translated into proteins. Because mRNAs encode all cellular proteins, oligonucleotides targeting mRNA could prove to be effective for targets and diseases that are not treatable by current drugs. For example, genetic diseases -in which the defect in the gene can be best repaired by manipulating DNA or RNA rather than the protein -such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) are two such diseases (discussed below). This Review covers the following three approaches that exploit oligonucleotides: RNA interference (RNAi), antisense oligonucleotides and steric-blocking oligonucleotides. These three approaches involve the binding of complementary oligonucleotides to target RNA through base pairing, and therefore all three are -in essenceoperating by an antisense mechanism. However, they differ substantially in their downstream mechanisms of action and the functional outcomes they produce.
RNAi and antisense oligonucleotides -which will be discussed only briefly as they have been extensively reviewed in the literature (see REFS 1,2) -modulate gene expression by inducing enzymatic degradation of targeted mRNA and the removal of the disease-causing gene product, such as an oncogene or a pro-inflammatory cytokine. As cellular enzymes need to recognize these antisense compounds, they can only be chemically modified to a limited degree, which limits our ability to enhance their pharmacological qualities. Antisense compounds that modulate RNA function by blocking the access of cellular machinery to RNA, and so do not lead to degradation of the target RNA, are the main focus of this Review. This different mode of action leads to outcomes such as the repair of a defective RNA or the generation of a novel protein, which cannot be achieved using RNAi or antisense oligonucleotides. Furthermore, because RNA-blocking oligonucleotides do not need to exploit cellular enzymes for their activity, they can be subjected to more extensive chemical modifications that improve their drug-like qualities.
The poor intracellular uptake of RNAi, antisense oligo nucleotides and steric-blocking oligonucleotides is a major impediment to their use as therapeutics. This is the main reason why the antiviral drug fomivirsen 3 is currently the only approved antisense drug (although the drug was discontinued in 2004 as the market for the drug diminished). Recent advances in chemistries that improve the intracellular delivery of antisense oligonucleotides, as RNA interference (RNAi) . A form of posttranscriptional gene silencing in which the expression or transfection of doublestranded RNA induces degradation by nucleases of the homologous endogenous transcripts, resulting in the reduction or loss of gene activity.
RNA therapeutics: beyond RNA interference and antisense oligonucleotides Antisense oligonucleotides
Oligonucleotides that bind to complementary mRNA by base pairing and induce cleavage of targeted mRNA by ribonuclease H, an enzyme that degrades RNA in RNA-DNA duplexes.
Small interfering RNAs
(siRNAs). Synthetic, short, 21-22-nucleotide-long double-stranded RNAs with chemical modifications designed to increase their stability and cellular uptake. One strand of siRNA hybridizes to targeted mRNA and allows mRNA degradation.
RNA-induced silencing complex
(RISC). A multiprotein complex that, when combined with small interfering RNA (siRNA), affects mRNA degradation. A key component of RISC is an endonuclease, argonaute 2, which cleaves the targeted mRNA within the siRNA-mRNA duplex.
well as differences that characterize the three technologies, are highlighted in this Review. Aptamers, which are more structurally complex than oligonucleotide RNA-based drugs, and interact directly with proteins rather than complementary RNA, are not covered in this article 4 .
Oligonucleotides that degrade target mRNA RNAi. RNAi was first demonstrated in a nematode 5 (Caenorhabditis elegans), in which the delivery of exogenous, long, double-stranded RNA (dsRNA) effectively silenced the expression of a gene (encoding a myofilament protein) by inducing the degradation of a homo logous host mRNA. The mechanism that mediated gene silencing involved degradation of dsRNA into small interfering RNAs (siRNAs) -double-stranded RNA fragments that are 21-22 nucleotides long and interact with a multiprotein RNA-induced silencing complex (RISC). Within the RISC, the siRNA is unwound, the sense strand is discarded, and the antisense or guide strand binds to mRNA. When siRNA is fully complementary to its target, the endo nuclease argonaute 2 -a component of the RISC -cleaves the mRNA 10 and 11 nucleotides downstream from the 5′ end of the antisense strand 6 (FIG. 1a) .
Although RNAi could not initially be detected in mammalian cells, later studies showed that these cells lacked the ability to cleave dsRNA into siRNA. The discovery that synthetic siRNA can enter the RISC and degrade targeted mRNA when delivered to cultured human cells 7 led to a rapid increase in the amount of research related to siRNA. In 2002, the first full year after the discovery of siRNA, a query for siRNA in PubMed resulted in 234 citations; for the 2002-2010 period it lists 33,009 citations, of which 7,241 were from 2010. Notably, a first successful in vivo study was carried out as early as 2003, using naked siRNA to knockdown FAS mRNA in a mouse model of fulminant hepatitis 8 . The increase in the amount of RNAi research also resulted in the founding of companies -such as Alnylam Pharmaceuticals and Sirna Therapeutics -focused on the development of siRNA as a promising therapeutic platform.
Systemically delivered unmodified siRNA is rapidly degraded by nucleases circulating in the bloodstream; it has a half-life in plasma of approximately a few minutes, and its uptake into target organs and cells is generally poor but it has shown some success in liver delivery 8 . Chemical modifications to promote metabolic stability and improve target cell penetration have been introduced to overcome such problems. However, it has become apparent that the interaction of siRNAs with the cellular RISC machinery presents a challenge for their use as therapeutics, because only limited chemical modifications can be introduced into siRNA for it to remain functional within the RISC. In the antisense strand, phosphorothioate internucleotide linkages at the 3′ end, and 2′-O-methyl (2′-OMe) nucleotide substitutions (FIG. 2) in one or two internal nucleotides, are tolerated and improve the resistance of the siRNA to nucleases. The sense strand can be modified more heavily (that is, more internal nucleotides can carry 2′-OMe nucleotide substitutions) without substantially reducing efficacy (reviewed in REF. 9 ).
Because of the difficulty in achieving intracellular delivery of siRNAs, they were administered locally in the majority of initial clinical trials. These included: intravitreal injection for the treatment of macular degeneration (ClinicalTrials.gov identifier: NCT00363714); intranasal delivery for respiratory syncytial virus (ClinicalTrials.gov identifier: NCT00658086); and direct injections in skin lesions for pachyonychia congenita, a rare genetic skin disorder (ClinicalTrials.gov identifier: NCT00716014). It was noted that intranasal delivery in humans results in only minimal systemic distribution of the drug 10 , indicating that in the absence of delivery agents unmodified siRNAs have a limited bioavailability in humans.
Two clinical trials that are currently underway aim to tackle the problems associated with systemic siRNA delivery by combining siRNA with delivery-enhancing agents. In one trial, a cocktail of two siRNAs, ALN-VSP02, has been formulated with lipid particles and targeted to mRNAs encoding kinesin spindle protein and vascular endothelial growth factor, which are essential for tumour proliferation and tumour-supporting angiogenesis, respectively (see the 4 June 2011 press release on the Alnylam Pharmaceuticals website; ClinicalTrials.gov identifier: NCT00882180). In the second trial (of CALAA-01), siRNA has been formulated in a cyclodextrin-adamantane polyethylene glycol particle that includes a targeting component, human transferrin protein, which targets the siRNA to ribonucleotide reductase mRNA (ClinicalTrials.gov identifier: NCT00689065). These delivery-enhancing moieties should improve the cellular uptake of siRNA; if successful, these clinical studies will be of substantial interest.
A series of lipid-based, liver-directed siRNA carrier particles was recently tested in a mouse model of haemophilia and in healthy cynomolgus monkeys. Systemic delivery of the formulated siRNAs reduced the levels of factor VII mRNA and glyceraldehyde-3-phosphate dehydrogenase mRNA at remarkably low doses of 0.01 mg per kg in mice and 0.1 mg per kg in monkeys, respectively 11 . A single high dose of the preparation was well tolerated in both species. As the effects of siRNAs were examined only in the liver, it is not known whether they were taken up by other tissues. Nevertheless, these results represent dramatic improvements in siRNA delivery to specific target tissues -in this case the liver.
Another problem associated with RNAi technology -which stems from mechanisms of RNAi -is the offtarget effects of siRNAs. Short dsRNAs, termed microRNAs (miRNAs), are produced in mammalian cells and as a class they control the efficiency of the translation of mRNAs. Synthetic siRNAs may interfere with this process, thus mimicking the effects of miRNAs. Specifically, siRNAs can enter the RISC and bind with certain base pairs mismatched to untargeted mRNAs, thus acting like endogenous miRNAs and leading to off-target gene silencing 12 . In addition, siRNAs can activate an innate immune response via activation of Toll-like receptors, leading to undesirable side effects such as the induction of pro-inflammatory cytokines or interferon-α 6, 12 . Taken together, these developments indicate that systemic Nature Reviews | Drug Discovery . Synthetic double-stranded siRNA is complexed with components of the RNA interference pathway, dicer, argonaute 2 (AGO2) and other proteins, to form an RNA-induced silencing complex (RISC). The RISC binds to a targeted mRNA via the unwound guide strand of siRNA, allowing AGO2 to degrade the RNA. The RISC-bound siRNA can also bind with mismatches to unintended mRNAs, leading to significant off-target effects (see main text). b | Antisense gapmer oligonucleotides. These commonly have a phosphorothioate backbone with flanks that are additionally modified with 2′-O-methoxyethyl (2′-MOE) or 2′-O-methyl (2′-OMe) residues (highlighted in red in figure) . Flank modifications increase the resistance of the antisense oligonucleotide (ASO) to degradation and enhance binding to targeted mRNA. The unmodified 'gap' in a gapmer-mRNA duplex is recognized by ribonuclease H (RNase H), a ribonuclease that degrades duplexed mRNA. c | Translation-suppressing oligonucleotides (TSOs). Phosphorodiamidate morpholino oligomers (PMOs) and their derivatives, or oligonucleotides fully substituted with 2′-MOE or 2′-OMe residues, are not recognized by RISC or RNase H and therefore do not lead to RNA degradation. Nevertheless, they lead to downregulation of gene expression via steric blockade of ribosome access to mRNA and suppression of protein translation. d | External guide sequences (EGSs) and RNase P. A peptide-conjugated PMO (PPMO) is designed to hybridize to targeted bacterial mRNA and form stem-loop structures such that the resulting duplex resembles tRNA.
In bacteria, a tRNA-processing ribozyme -RNase P -recognizes this structure and cleaves mRNA. delivery of chemically modified siRNA is not very effective and that more work will be needed to achieve sufficient therapeutic activity and specificity in the absence of delivery agents. It has now been over a decade since the discoveries of RNAi and siRNAs but despite some promising clinical trial results the industry remains cautious about the therapeutic potential of RNAi-based drugs. For example, although Merck acquired Sirna Therapeutics for US$1.1 billion, it was quoted in 2009 as remaining sceptical about the development of siRNA-based drugs 13 ; meanwhile, Roche, Novartis and Pfizer 14 decided to dramatically reduce or eliminate their RNAi research programmes, which raised the question "Is RNAi dead?" in a 2011 editorial 15 (see the article on the GenomeWeb website, and the article on the Proactive Investors website). This is reminiscent of a previous question -"Does antisense exist?" -that was raised in a commentary in 1995 (REF. 16 ). The history of antisense oligonucleotides
, which now seem to be well on their way to becoming drugs, suggests that RNAi will eventually succeed as a therapeutically viable technology. As a possible harbinger of further progress, an upcoming clinical trial will test chemically modified siRNA for the treatment of diabetic macular oedema (ClinicalTrials.gov identifier: NCT01445899).
Antisense oligonucleotides. Since the first application of a short fragment of unmodified DNA in cell culture as an antisense oligonucleotide, by Zamecnik and Stephenson 17 in 1978, remarkable progress has been made in oligonucleotide drug development. Numerous chemical modifications that improve the drug-like properties of DNA have been introduced
, an antisense drug has been marketed and successful clinical trials are underway, as described below. Currently, a typical antisense oligonucleotide drug candidate is about 20 nucleotides long and has a phosphorothioate linkage (FIG. 2) between the nucleosides that form the backbone. In addition, five nucleotides at each flank are further modified (FIG. 2) to protect the antisense oligonucleotide from exonucleases, thus increasing its stability in vivo. This design leaves a central 10-nucleotide phosphorothioate gap (hence the term 'gapmers') that allows the cleavage of targeted mRNA by ribonuclease H (RNase H) 18 (FIG. 1b) . The modified flanks also improve the binding of the antisense oligonucleotide to mRNA and reduce the side effects that are associated with the presence of phosphorothioate residues
.
In contrast to siRNA, which tolerates only limited modifications to remain RISC-compatible, more extensive chemical modifications in gapmers do not abrogate RNase H activity. One such modification, 2′-O-methoxyethyl (2′-MOE) ribonucleoside (FIG. 2) , is present in two antisense oligonucleotides that have recently been successful in clinical trials: mipomersen (also known as ISIS 301012) and custirsen (also known as OGX-111) 19, 20 . Mipomersen is a 2′-MOE phosphorothioate antisense oligonucleotide gapmer that targets mRNA encoding apolipoprotein B100 (APOB100) expressed in the liver; APOB100 is a protein that is involved in the production of low-density lipoprotein cholesterol (LDL-C; also known as 'bad' cholesterol). Mipomersen reduces the levels of APOB100 secreted from liver cells into the bloodstream. In a recent Phase III trial, mipomersen lowered LDL-C levels by ~25% in patients with homozygous familial hypercholesterolaemia who had very high LDL-C levels (up to 300 mg per dl); by comparison, placebo treatment lowered LDL-C levels by ~3%. Twenty-six out of thirty-four treated patients incurred injection-site reactions, and four had a significant increase in alanine aminotransferase levels, which is indicative of liver stress 19 . These signals need to be carefully monitored, especially in a chronic disease.
Custirsen is also a phosphorothioate antisense oligonucleotide gapmer with 2′-MOE flanks, and it targets the mRNA encoding clusterin, an anti-apoptotic chaperone protein that is upregulated in cancer cells. Significant declines in serum levels of clusterin were seen in the Phase II trial of custirsen in patients with advanced metastatic prostate cancer; the trial included 41 patients in each arm, and patients were treated with a combination
Box 1 | The ups and downs of antisense oligonucleotides
In 1978 Zamecnik and Stephenson 17, 96 found that a 13-nucleotide-long oligodeoxynucleotide that was complementary to a target sequence in Rous sarcoma virus RNA inhibited viral replication and protein translation in vitro; the field of antisense oligonucleotides was born. Remarkably, in this pioneering work the authors even introduced chemical modifications at the 3′ and 5′ ends of the oligonucleotide to reduce its degradation by cellular nucleases, which improved its activity, and they demonstrated that the same antisense oligonucleotide used against another avian virus was less effective, presumably because the three mismatches in the target sequence weakened its binding. Thus, two key themes -improvements in antisense oligonucleotide efficacy via chemical modifications, and the need for specificity controls -were established at the very birth of the field.
It took almost 10 years before the next major advancement in the field. The most consequential was the introduction of phosphorothioate internucleotide linkages 97 (FIG. 2) , followed by the addition of 2′-O-methyl-modified nucleotides at the 3′ and 5′ ends, which protected the antisense oligonucleotides from degradation by nucleases 98 . These modifications dramatically increased the stability of antisense oligonucleotides in cell culture and in vivo, while still allowing ribonuclease H (RNase H)-mediated cleavage of RNA in phosphorothioate antisense oligonucleotide-RNA duplexes (reviewed in REF. 18 ). Several phosphorothioate antisense oligonucleotide drug candidates progressed through various stages of drug development but only one -fomivirsen -was registered (in 1998) as a treatment for cytomegalovirus-induced retinitis in immunocompromised patients with AIDS. The drug, a 21-mer oligonucleotide, was delivered via intraocular injection. This choice of indication and delivery contributed to the success of the drug. Intravitreal distribution of the drug dramatically limited the necessary dose (330 μg per 0.05 ml) and eliminated systemic exposure of the patient to the drug, thus avoiding any potential side effects. Consequently, 20 years after Zamecnik's discovery, the first antisense drug reached the market 3 . Although off-target effects have not been a serious issue for phosphorothioate antisense oligonucleotides, this backbone imparts a significant, hybridization-independent toxicity profile that varies with different sequences. The effects include increased coagulation time, pro-inflammatory effects and activation of the complement pathway. At higher concentrations, phosphorothioate antisense oligonucleotides lead to renal tubule changes and thrombocytopaenia 99 . In addition, phosphorothioate antisense oligonucleotides that contain certain sequences induce a strong immunostimulatory response through their interactions with Toll-like receptors 100 or they bind directly to proteins, leading to unexpected spurious effects. These results led to an article entitled: "Does antisense exist?" 16 . Some companies continued the development of phosphorothioate antisense oligonucleotides until very recently.
Oblimersen, which was developed by Genta as a potential anticancer drug, is one such example. Oblimersen targets the mRNA of the gene encoding B cell lymphoma 2 (BCL-2), an anti-apoptotic protein that is overexpressed in numerous cancers. It is noteworthy how difficult the attempts have been to bring oblimersen to market. Searching the ClinicalTrials.gov database for oblimersen shows that since 1999, this drug has been tested in 45 clinical trials. Unfortunately, recent trials for the treatment of advanced melanoma and myeloma, which enrolled almost 1,000 patients, demonstrated either very modest effects of the drug (for the treatment of melanoma) or no effect of the drug 101, 102 (for the treatment of myeloma). These efforts were certainly costly. In April 2002 Genta and Aventis (now Sanofi) entered into a development agreement for oblimersen that was valued at the time at US$480 million (See the article on the Forbes website). Today, Genta's stock is no longer listed on a regular NASDAQ stock exchange board, and the oblimersen programme was terminated after additional trials missed the expected primary targets 103 .
External guide sequence (EGS). A short RNA sequence designed to bind to targeted mRNA and form a structure that is recognized by a tRNA-processing ribozyme, ribonuclease P. Ribonuclease P cleaves mRNA and thereby downregulates the function of a targeted gene.
Splice-switching oligonucleotides
(SSOs). Chemically modified oligonucleotides that block sequences in pre-mRNA that are involved in pre-mRNA splicing, and redirect mRNA splicing pathways. SSO-pre-mRNA duplexes are not recognized by ribonuclease H or the RNA-induced silencing complex, and the pre-mRNA is thus not cleaved.
Alternative splicing
Splicing of pre-mRNA to yield more than one kind of mRNA -that is, different splice variants -by frequently including or excluding an exon.
Translational reading frame
Arrangement of mRNA nucleotides into triplets (codons) that, when read by the ribosome, are translated into one amino acid per codon. The reading frame usually starts with a translation initiation codon, AUG -for example, AUG UUU ACA GCA. Deletion of a nucleotide, such as the third uridylic in the second codon, changes the reading frame to AUG 'UUA CAG CA', thus preventing the translation of the desired protein.
of custirsen and docetaxel or docetaxel alone 20 . Custirsen was well tolerated, although fever was observed in some patients. The most encouraging outcome was the increase in median overall survival in patients treated with custirsen, which was ~24 months compared with ~17 months for patients treated with docetaxel alone. Differences in other measures were not statistically significant. Nevertheless, on the strength of these results two Phase III trials were initiated (see the 30 September 2010 press release on the OncoGenex website). Custirsen was not effective in a Phase II study of women with metastatic breast cancer 21 , suggesting that the efficacy of the drug may be cancer-specific.
The first-generation antisense phosphorothioate drug fomivirsen was approved 20 years after the discovery of the first antisense oligonucleotide; if custirsen and mipomersen are approved in the near future, another 10 years will have elapsed from the approval of fomivirsen to the approval of these new, second-generation, gapmertype antisense drugs. This timescale is similar to that for the development of monoclonal antibodies -another class of macromolecular drugs
. See TABLE 1 for a comparison of the RNA therapeutics discussed in this Review.
Steric-blocking oligonucleotides
In parallel to the development of gapmer antisense oligonucleotides, oligonucleotides were developed that do not induce RNase H-mediated cleavage of mRNA but instead act by blocking targeted RNA without inducing its degradation. Early examples of these oligonucleotides included oligonucleoside methylphosphonates 22 and phosphorodiamidate morpholino oligomers 23 (PMOs) (FIG. 2) . The outcomes of this approach depend on the nucleotide sequence elements in mRNA or pre-mRNA that are targeted. These outcomes can include modulation of splicing when pre-mRNA is targeted, blockade of mRNA translation or RNA folding, and external guide sequence (EGS)-directed mRNA degradation by a tRNAprocessing ribozyme, RNase P. They can also be used to block toxic RNAs that would otherwise sequester protein factors at their expanded triplet repeats (FIGS 1,3 ). These applications are highlighted below.
Splice-switching oligonucleotides. Oligonucleotideinduced modulation of splicing leads to several outcomes in cell culture and in vivo that have potential therapeutic value. These outcomes are not achievable with siRNA or classic gapmer antisense oligonucleotides, which only downregulate gene expression. Spliceswitching oligo nucleotides (SSOs), oligonucleotides that modulate pre-mRNA splicing, can repair defective RNA and restore the production of essential proteins; they can also generate novel proteins with desirable properties and regulate the presence of disease-related splice variant proteins. The latter outcome is achieved by modulation of alternative splicing of pre-mRNA. As over 95% of all human genes produce splice variant proteins by alternative splicing, modulation of alternative splicing may be applicable to a multitude of diseases 24 .
To modulate pre-mRNA splicing, oligonucleotides must block RNA sequences that are essential for splicing and prevent the interaction of splicing factors -such as RNA-binding proteins, small nuclear RNAs and other components of the spliceosome -with the premRNA
. The chemistries that have been shown to work in animal models include peptide nucleic acids (PNAs), alternating locked nucleic acids (LNAs) and deoxynucleo tide oligonucleotides, fully modified (nongapmer) 2′-substituted oligonucleotides and PMO-based oligomers [25] [26] [27] [28] (FIG. 2) . The latter two SSO chemistries have been used in clinical trials that tested splicing modulation as a treatment for DMD [29] [30] [31] [32] (FIG. 3a) .
Duchenne muscular dystrophy DMD is a severe genetic disorder that affects one in 3,500 newborn males. It causes muscle wasting that leads to loss of mobility by 10-12 years of age, and death in the mid-20s resulting from failure of respiratory and cardiac functions. The genetic defects that underlie DMD are mostly DNA deletions within the gene that encodes dystrophin, a protein that connects intracellular actin filaments to the sarcolemma membrane and as such is essential for maintaining the integrity of that membrane. In its absence, muscle fibres disintegrate at a rate that outpaces muscle regeneration mechanisms.
In most cases of DMD, the deletions disrupt the translational reading frame, thus abrogating expression of the dystrophin protein. By contrast, in a milder form of the disease, Becker muscular dystrophy (BMD), the deletions mostly preserve the reading frame, allowing the production of truncated but partially functional dystrophin. Remarkably, even though the mutant dystrophin produced in BMD may have large internal deletions, and is produced at levels below normal, its activity is largely sufficient to retain muscle function; in some affected individuals muscle function is close to normal. This observation indicates that a drug that could partially restore the function of dystrophin protein could be of clinical value for the treatment of DMD (reviewed in REFs 33, 34) .
With 2.4 million base pairs, the dystrophin gene is the largest gene in humans. It comprises 79 exons, 34 of which encode full codons (termed here as in-frame exons). Deletion of an in-frame exon (or exons) does not disrupt the overall reading frame, and allows translation of dystrophin that retains the correct amino acid sequences at the termini of the molecule but is missing its internal portion. Such deletions usually are found in patients with BMD. In the remaining 45 exons the last, first or both terminal codons are split between the two adjacent exons. Most of these exons are out-of-frame and, in contrast to most in-frame exons, their deletion disrupts translation of the dystrophin protein and so causes DMD. The same is true for a deletion that starts at an in-frame exon but ends in an out-of-frame exon 33 . It follows, therefore, that SSO-induced skipping of the adjacent out-of-frame exon should restore the reading frame and convert severe DMD to the milder form of the disease, BMD 35 (FIG. 3a) . This approach would be applicable to about 85% of patients with DMD, as some mutations cannot be corrected by exon skipping.
For example, from the patient population that responds to exon skipping, about 17% of patients with deletions that include of out-of-frame exons 50 or 52 would benefit from the skipping of exon 51 and the restoration of the reading frame. SSO-induced skipping of four more exons (exons 44, 45, 50 and 53) could benefit an additional 27% of patients from this population 36 .
PMO and 2′-OMe phosphorothioate. The proof of concept of exon skipping in DMD was demonstrated over 10 years ago 37 by the treatment of muscle cells from an mdx mouse -a mouse with muscular dystrophy caused by a nonsense mutation in exon 23 of the dystrophin gene 38 -with 2′-OMe phosphorothioate SSOs. Following this finding, similar results were obtained in These are short RNA-forming structured complexes with targeted mRNA that are recognized by a tRNA-processing enzyme, ribonuclease P. . 2′-OMe phosphorothioate SSOs and PMO SSOs were subsequently tested by systemic administration in mdx mouse and dog models of DMD 26, [42] [43] [44] . In mdx mice, PMO SSOs were more effective than 2′-OMe phosphorothioate SSOs at restoring the reading frame of dystrophin mRNA 42, 43 . A single intravenous dose (80 mg per kg) of PMO SSOs induced dystrophin expression in about 25% of muscle fibres in the quadriceps, which was the muscle that responded best to treatment. Seven weekly injections increased the percentage of muscle fibres that expressed dystrophin to over 80%. A three-dose treatment improved tibialis anterior muscle function to nearly 80% of normal, even though the level of dystrophin in this muscle was only 20% of normal. This is an important result, as it suggests that below-normal dystrophin levels may still be clinically beneficial.
PMO SSOs were also effective in a dog model of DMD 44 . Importantly, this study demonstrated the efficacy of exon skipping in a large animal, showing clear improvements in the mobility of the dog. Although an untreated dog had difficulty finishing a 15-metre run, a dog treated with five weekly injections (at a dose of 120 mg per kg) ran quickly and completed the course without difficulty. This performance was achieved when dystrophin levels in the muscles of the treated animals were -on average -26% of normal, thus confirming with a more challenging animal model that complete restoration of dystrophin is not essential for clinically relevant effects. In both the dog and mouse models of DMD, 2′-OMe phosphorothioate SSOs were less effective. For example, a single intravenous injection of the compound (at a dose of ~80 mg per kg) resulted in less than 10% of fibres that were dystrophin-positive in the quadriceps of the mdx mouse. Nevertheless, both 2′-OMe SSOs and PMO SSOs entered into clinical trials as a treatment for DMD. These trials have recently been extensively appraised (reviewed in REF. 45 ) and so will be discussed here only briefly.
In trials that tested the safety of the drug, which was administered by single, intramuscular injections, 2′-OMe phosphorothioate SSOs (PRO-051) 29 and PMO SSOs (AVI-4658) 30 were delivered into the tibialis anterior and extensor digitorum brevis muscles, respectively. Both drugs caused accurate skipping of exon 51: PRO-051 at 0.8 mg, and AVI-4658 at two doses, 0.9 mg and 0.09 mg. Importantly, with both drugs the dystrophin protein was correctly localized to the muscle fibre membranes, irrespective of the size of the exon deletions in individual patients, which varied from five exons (exons [45] [46] [47] [48] [49] [50] , to a single exon (exon 50). This indicated that the rescued dystrophin was functional in every patient, as it reconstituted a dystroglycan complex that is normally located in the sarcolemma of healthy muscle. AVI-4658 produced a statistically significant increase in dystrophin-positive fibres, which was up to 79% of normal and above the background of the control sample from a saline-treated contralateral extensor digitorum brevis muscle. In the PRO-051 trial, up to 97% of muscle fibres were dystrophin-positive. However, this study lacked a negative control, which made quantitative analysis of newly generated dystrophin questionable.
PRO-051 and AVI-4658, given systemically, were also evaluated in clinical trials 31, 32 . In a Phase I/IIa trial, PRO-051 was initially delivered weekly by subcutaneous injection for 5 weeks at doses of 0.5-6.0 mg per kg. In a continuation study, all patients were treated 6-15 months later with a weekly dose of 6.0 mg per kg, and results were reported after 12 weeks. In support of the proof of principle for exon-skipping therapy, muscle biopsy samples collected after the last injection showed the presence of dystrophin-positive fibres in most patients. However, because background control pretreatment biopsy samples were collected for only a few subjects, the validity of the assessment was again debatable. The improvement in the clinical status of the patients was measured by a 6-minute walk test after the additional 12-week treatment. A slight but not statistically significant increase in the distance covered was noted 31 . In a Phase II trial, AVI-4658 was systemically delivered by weekly intravenous infusion at doses ranging from 0.5-20.0 mg per kg for 12 weeks; pre-and posttreatment biopsy samples were collected from every patient. Seven patients responded well to treatment; their mean dystrophin fluorescence intensity increased from 8.9% to 16.4% of normal (control). One patient treated with 20 mg per kg of AVI-4658 exhibited 55% of dystrophin-positive fibres over negative control. Overall, there was a significant dose-dependent increase A chemically modified, RNA-blocking oligonucleotide targeted to a splice site or an exon-internal exonic splicing enhancer (ESE) in pre-mRNA prevents the proper assembly of the spliceosome on the exon and redirects splicing to another pathway, inducing skipping of the targeted exon. Such alternatively spliced mRNA may encode a novel protein with favourable properties, or it may restore translation if exon skipping restores a reading frame, as is the case in Duchenne muscular dystrophy; alternatively, it may change the balance of alternative splice variants. These outcomes cannot be accomplished by antisense oligonucleotides or small interfering RNA, which degrade targeted mRNA. b | Exon retention by SSOs. Some exons are poorly spliced into mRNA because they contain exonic splicing silencer (ESS) elements. An SSO designed to block an ESS interferes with this element's role in splicing and promotes exon inclusion, as has been demonstrated in the case of spinal muscular atrophy, a genetic disorder. c | Restoration of correct splicing and RNA repair by SSOs. An intron mutation may create and/or activate aberrant splice sites, leading to the inclusion of an intronic fragment into the spliced mRNA, in essence creating a pseudo-exon and interfering with the translational reading frame. An SSO targeted to the aberrant splicing elements restores correct splicing and allows translation of the correct, fully functional protein. d | Displacement of splicing factors from triplet repeats. An extended triplet repeat (CUGCUGCUG) in dystrophia myotonica protein kinase (DMPK) pre-mRNA attracts splicing factors known as muscleblind-like proteins (MBNLs), and titrates them out from the nucleoplasm. As a result, DMPK and several other pre-mRNAs are not properly processed, which prevents the translation of several proteins and causes myotonic dystrophy, a neuromuscular disorder. A modified steric-blocking oligonucleotide displaces MBNL, allowing it to participate in the splicing of appropriate mRNAs and restoring function in the affected muscle. ▶ in new dystrophin protein in the muscle biopsy samples. Furthermore, there was a dose-dependent, statistically significant decrease in inflammatory infiltrates in the biopsy material, suggesting that restoration of dystrophin -even at low levels -ameliorates certain aspects of the disease. Similarly to 2′-OMe phosphorothioate SSOs, PMO SSOs did not result in a statistically significant increase in distance covered in the 6-minute walk test pre-versus post-treatment 32 . The above two clinical studies also highlight the differences between the PRO-051 and AVI-4658 chemistries in terms of tolerability. AVI-4658 was well tolerated and there were no reported drug-related adverse effects at any dose 32 . However, all patients treated in a continuation study with PRO-051 for 12 weeks (at 6 mg per kg) exhibited proteinuria, which is a possible sign of drugrelated kidney damage 31 . The safety of AVI-4658 was further confirmed in animal studies. At doses of up to 320 mg per kg in monkeys and up to 960 mg per kg in mice, there were no observable toxic effects 46 . In mdx mice, there was no PMO SSO-induced toxicity after a single injection, even at 3 g per kg of body weight 47 . A study of the pharmacokinetics and pharmacodynamics of a 2′-OMe phosphorothioate SSO that induced the skipping of exon 23 in mdx mice demonstrated high accumulation of the compound in kidneys and the liver; however, an analysis of potential toxic effects in these organs was not reported 48 .
Peptide-conjugated PMOs. PMO SSOs did not generate appreciable levels of dystrophin in the heart of dystrophic dogs 44 and, even with high doses, they only generated low levels of dystrophin in the hearts of mdx mice 47 . Considering that patients with DMD usually die of heart or respiratory failure, this is an important issue. The synthesis of improved, second-generation, peptide-conjugated PMOs (PPMOs) (FIG. 2) was therefore a significant advancement. In mdx mice, a PPMO (AVI-5225) that included a positively charged, argininerich peptide was superior to PMO and other chemistries at generating dystrophin 49 . When administered at a dose of 12.5 mg per kg, it skipped exon 23 in mdx mice and restored dystrophin protein expression in skeletal muscles to levels that were close to normal, which remained unchanged for up to 11 weeks. The PPMO treatment led to a long-term reduction in cardiac hypertrophy 50 and also prevented heart failure in mdx mice that were challenged with the β-adrenergic receptor antagonist dobutamine; by comparison, 60% of untreated mice died 51 . Even more convincing evidence for the high efficacy of PPMO-induced exon skipping was obtained using a double-knockout mouse deficient in both utrophin and dystrophin that displayed very severe muscular dystrophy. As they also lack utrophin, a muscle protein that partially compensates for the lack of dystrophin in mdx mice, these double-knockout mice are largely immobile and have an average lifespan of 8.2 weeks, compared with about 2 years for mdx mice. Treatment with a PPMO targeted to exon 23 and administered at a dose of 25 mg per kg per week for 6 weeks, beginning at 10 days of age, dramatically increased the animals' mobility, food-seeking behaviour and the turgor of the tail to close to normal values 52 . Variants of arginine-rich PPMOs that are particularly effective at restoring dystrophin expression in the heart muscle of mdx mice have been recently reported 53 . It should be noted that in a preliminary study in monkeys, 12 weekly doses of a PPMO targeted to exon 50 of the dystrophin gene resulted in kidney toxicity, which was not observed following a 4-week treatment (see the 25 March 2010 press release on the AVI BioPharma website). As PMO at the core of PPMO is very stable in serum, intracellularly 54 and in vivo (R.K. and C. Eckhoff, unpublished observations), it seems possible that less frequent dosing may reduce the accumulation of the compound in the kidneys and alleviate kidney toxicity.
Other indications for SSOs
The therapeutic application of SSOs is most advanced in DMD but, as described in more detail below, these compounds are also being studied as potential treatments for two other genetic diseases -SMA and β-thalassaemia -as well as for rheumatoid arthritis, a major inflammatory condition. Although in each condition a desired outcome is the production of a functional protein, a different mechanism of splicing modulation is exploited to
Box 2 | Pre-mRNA splicing as a therapeutic target
The discovery of RNA splicing 104, 105 was followed by the identification of an intronic mutation in the human β-globin gene, which corrupted the splicing of β-globin pre-mRNA even though the natural splice sites were not mutated and remained potentially functional 106, 107 . This defect prevented the proper translation of the β-globin protein, causing β-thalassaemia -a genetic blood disorder. The single point mutation in intron 1 of the β-globin gene created an additional aberrant 3′ splice site, which redirected the spliceosome away from the natural 3′ splice site. This aberrant splicing pathway, which occurred even though the correct 3′ splice site was still present in the pre-mRNA, suggested that splice site selection occurs by competition between splice sites for the components of the spliceosome assembling on the pre-mRNA. If this hypothesis was correct it seemed likely that blocking the aberrant 3′ splice site with an oligonucleotide might redirect the spliceosome back to the natural splice site, thus restoring proper splicing and translation of the β-globin protein, with obvious potential for clinical application. This ability to repair the RNA and resurrect the missing protein, leading to amelioration of the disease, is the key distinguishing feature of oligonucleotide-induced modulation of pre-mRNA splicing. It cannot be achieved by small interfering RNA or classical antisense gapmer oligonucleotides, which lead only to degradation of the targeted RNA 25 . The discovery of alternative splicing showed that this mechanism of competition between splice sites is not limited to just mutant genes but it also controls the expression of the vast majority of native, properly functioning genes 108 . Thus, splice-switching oligonucleotides form a basis for a platform technology with the potential to treat many diseases.
The repair of defective β-globin pre-mRNA, which restored the correct splicing of β-globin mRNA, was first demonstrated in splicing extracts from HeLa cells 65 . Systemically delivered splice-switching oligonucleotides have been proven to be effective in vivo in animal models of β-thalassaemia 67, 68 , spinal muscular atrophy [61] [62] [63] and Duchenne muscular dystrophy 26 -three devastating genetic disorders that affect children. More importantly, the application of splice-switching oligonucleotides as drugs for the treatment of Duchenne muscular dystrophy has already been tested in clinical trials via intramuscular administration 29, 30 , and in recently completed clinical trials via systemic administration 31, 32 .
Exonic splicing silencers
Sequences present in exons in pre-mRNA that contribute to the modulation of splicing. They can inhibit the inclusion of a given exon into mature mRNA during splicing. Exonic splicing enhancers also exist.
Intronic splicing silencers
Sequences present in introns in pre-mRNA that contribute to the modulation of splicing. They can inhibit the inclusion of a given intron into mature mRNA during splicing. Intronic splicing enhancers also exist. achieve this goal. In SMA the SSOs block either exonic splicing silencers or intronic splicing silencers to promote the inclusion of an otherwise skipped exon (FIG. 3b) . In β-thalassaemia an aberrant splice site is blocked and splicing is redirected to the correct pathway (FIG. 3c) . In rheumatoid arthritis a functional tumour necrosis factor (TNF) receptor is converted by exon skipping into a soluble decoy receptor that inhibits TNF activity. This flexibility in the possible approaches indicates that SSO-induced modulation of splicing has the potential to be clinically beneficial in many diseases.
SMA. SMA is a genetic neuromuscular disease with an incidence of approximately one in 6,000 live births. It is characterized by the loss of lower motor neurons in the spinal cord and results in progressive paralysis and muscle atrophy. There is no treatment for this disorder, which in its severest form leads to early infant death. The disease is caused by mutations in the survival of motor neuron 1 (SMN1) gene, which encodes SMN, a protein that is essential for the preservation of motor neuron integrity 55 . Humans also carry SMN2, a very closely related variant of the SMN1 gene, but SMN2 produces SMN protein only in low amounts and is insufficient to fully compensate for the loss of SMN1-derived protein.
The low activity of the SMN2 gene is caused by a translationally silent mutation that weakens the recognition of exon 7 by the splicing machinery and prevents its inclusion into SMN2 mRNA during splicing 56 . A systematic screen of 2′-MOE phosphorothioate SSOs targeted to exon 7 of SMN2 pre-mRNA identified a compound that blocked an exonic splicing silencer located in exon 7, and therefore increased the inclusion of the exon and resulted in the restoration of SMN protein expression in cell culture 57 (FIG. 3b) . Highly effective 2′-MOE phosphorothioate SSOs targeting intronic splicing silencers in the introns flanking exon 7 of SMN2 were also identified 58, 59 . In a mouse model of SMA, 4 weeks of systemic SSO administration increased the inclusion of exon 7 of SMN2 by approximately fivefold in the liver, threefold in the kidney and twofold in the quadriceps of treated mice 59 . As oligonucleotides do not seem to cross the blood-brain barrier 27 , it was not surprising that there was no effect in the spinal cord -the key therapeutic target tissue. Nevertheless, the experiments provided an important in vivo proof of principle for the treatment of the disease, and demonstrated that SSOs can be used for both exon skipping and exon retention.
To bypass the blood-brain barrier, 2′-OMe phosphorothioate SSOs 60 or 2′-MOE phosphorothioate SSOs 61, 62 were directly delivered via intracerebroventricular injections into embryos or newborn pups of mice with SMA. This produced striking results: SSOs were distributed throughout the central nervous system (CNS), including the spinal cord. They also led to improvements in the righting response of the mice and delayed the onset of tail and ear necrosis. In the next step towards clinical trials, intrathecal and intracerebroventricular infusions of 2′-MOE phosphorothioate SSOs delivered the compound to the spinal cord in monkeys. This tissue contained >8 μg per g of the oligonucleotide, which is the level anticipated to have therapeutic effects based on the results obtained from the mouse models 62 . If the SSO passes the US Food and Drug Administration (FDA)-mandated safety tests in animals, clinical tolerability and efficacy trials in humans will follow. As there is little evidence that large, charged oligonucleotides can traverse a mature blood-brain barrier, one could assume that the use of SSOs in patients with SMA will require intrathecal delivery. However, an unexpected finding suggests otherwise: a recent study showed that systemic delivery of 2′-MOE phosphorothioate SSOs resulted in a much more striking phenotypic rescue than intracerebroventricular delivery in a mouse model of severe SMA 63 . Intracerebroventricular administration of SSOs efficiently restored SMN expression in the CNS, including in motor neurons, but only increased mean survival from 10 to 17 days, which was consistent with earlier results in another mouse model 62 . By contrast, subcutaneous SSO administration increased the mean survival to 250 days, with some mice surviving longer than 1 year, even though only limited splicing correction was observed in the CNS. Combined intracerebroventricular and systemic administration was slightly better than systemic administration alone. These data suggest that, at least in this mouse model, the defects not only in the motor neurons but also in other tissues contribute to SMA. Low levels of circulating insulinlike growth factor 1 (IGF1) -which is synthesized in the liver -observed in this animal were attributed to reduced mRNA levels of the IGF-binding protein acid labile subunit (IGFALS). Systemic antisense oligonucleotide treatment restored IGFALS mRNA and IGF1 protein levels to normal. Given that IGF1 has neurotrophic activity, these results illustrate how pleiotropic peripheral defects in conjugation with SMN defects could contribute to motor neuron disease in SMA.
The extent to which these recent observations in mice with severe SMA are clinically relevant remains to be determined. This in turn will determine whether systemic SSO administration -alone or in combination with intracerebroventricular administrationshould be tested in clinical trials. Such an approach will require additional safety and tolerability studies, mandated by regulatory authorities, in non-human primates before such trials could be conducted. Nevertheless, a treatment for this devastating disease appears to be on the horizon. β-thalassaemia. β-thalassaemia is caused by mutations in the β-globin gene that decrease the production of β-globin, a subunit of haemoglobin, resulting in insufficient levels of haemoglobin to carry oxygen throughout the body 64 . This decrease also results in an excess of the α-globin subunit, which contributes to the damage to red blood cells. Blood transfusions are currently the main form of treatment, but in developing countries -where the disease is prevalent -these carry the risk of bloodborne infections. Most common mutations induce aberrant splicing of β-globin pre-mRNA, which abrogates correct translation of the β-globin protein 64 . One such mutation in nucleotide 654 of intron 2 (IVS2-654) of
Cryptic splice site
A splice site that is not functional under normal conditions but becomes activated if a mutation modifies its sequence to resemble a functional splice site or if an adjacent normal splice site is inactivated by a mutation.
β-globin pre-mRNA creates a new 5′ splice site and concomitantly activates a pre-existing 3′ cryptic splice site, leading to the retention of a pseudo-exon in the spliced mRNA (FIG. 3c) .
In 1993 it was demonstrated that correct splicing can be restored in vitro by SSOs targeted to β-globin premRNA 65 , but obtaining results in vivo proved to be difficult to achieve. Several chemistries (for example, 2′-OMe phosphorothioate, PNAs and PMOs) were ineffective in the delivery of the SSO to erythroid progenitor cells in a transgenic mouse model of IVS2-654 β-thalassaemia 66 . The only effective SSO variant was a PPMO. A 3-week intravenous treatment course with the PPMO caused a sixfold increase in the levels of correctly translated human β-globin mRNA compared with the control. The mRNA was properly translated in circulating red blood cells, and their morphology was improved 67 . An elegant follow-up to this work was the treatment of IVS2-654 mice with siRNA, which lowered the production of α-globin subunits, combined with a vector expressing antisense RNA that modulated the splicing of IVS2-654 β-globin pre-mRNA and increased the levels of β-globin. This combination led to a detectable increase in haemoglobin production in treated IVS2-654 mice 68 . Clearly, replacing blood transfusions with an oligo nucleotide that restores haemoglobin production would provide a substantial improvement for individuals with β-thalassaemia.
β-thalassaemia is one the most common genetic disorders worldwide, particularly in South East Asia 69 , and in China IVS2-654 is the most common mutation in the gene encoding β-globin 68 . However, because of the economic status of the affected countries there is apparent little commercial interest in advancing these new treatment options. Given the current high cost of oligonucleotides and/or gene therapy, it remains to be seen whether China and other Asian countries will accept treatments that -if developed -would currently be very expensive.
Alternative splicing
Although the above examples highlight the application of SSOs to the repair of defective mRNA for the possible treatment of genetic disorders, these compounds may also be used to manipulate alternative splicing of genes that are not defective or mutated. As most genes use alternative splicing to express multiple isoforms of mRNA and consequently proteins, this approach could have broad applicability. In early studies, manipulation of splicing was tested in vitro in cancer cell lines by switching the splicing pattern of B cell lymphoma X (BCL-X; also known as BCL2L1) pre-mRNA from anti-apoptotic BCL-X L to pro-apoptotic BCL-X S splice variants 70, 71 . This principle was tested in vivo in mouse models of inflammatory disease via oligonucleotideinduced skipping of exon 7 in the pre-mRNA of TNF receptor 2 (TNFR2).
Exon 7 in TNFR2 pre-mRNA encodes a transmembrane domain in the membrane-bound receptor protein. The removal of this domain has a dual effect: it generates a soluble, secreted form of the receptor (Δ7TNFR2), which acts as a decoy receptor by binding to TNF and removing it from the bloodstream; and it reduces the level of functional, membrane-bound TNFR2. TNFR2 mediates the activity of TNF, a cytokine that is induced in rheumatoid arthritis, psoriasis and other inflammatory diseases. In mice, injections of exon 7-targeted oligonucleotides with an LNA backbone (FIG. 2) (at a dose of 25 mg per kg) induced high levels of Δ7TNFR2, which persisted in the circulation for 30 days. This treatment prevented TNF-induced acute liver inflammation, and delayed the onset and reduced the severity of collagen-induced arthritis 72 . LNA SSOs could potentially be injected less frequently than the currently marketed drug etanercept (Enbrel; Amgen/ Pfizer), and because patients would express their own Δ7TNFR2 the potential for an immune response would be reduced. Another recent approach involved reducing TNF levels directly via an oligonucleotide that intercalates into the DNA of the TNF gene and inhibits its expression 73 .
Non-SSO steric-blocking oligonucleotides Myotonic dystrophy. Several neuromuscular diseases, including Huntington's disease, spinocerebellar ataxia and myotonic dystrophy, are caused by the expansion of triplet repeats, most frequently CTG and CAG. In healthy individuals the repeats are 5-35 triplets in length but this number may increase in their descendents and cause disease when the expansion reaches 80 to >2,500 repeats. Although Huntington's disease and ataxias are characterized by defective proteins that cause disease, in myotonic dystrophy the CTG repeat is in the 3′ untranslated region of the gene encoding dystrophia myotonica protein kinase (DMPK), andin principle -the correct DMPK protein could still be produced. However, the repeat generates a defective, expanded CUG repeat-containing mRNA that is not correctly spliced and accumulates in the cell nucleus in distinct foci, preventing the export of DMPK mRNA to the cytoplasm 74 . More importantly, the repeat in the accumulated expanded CUG repeat-containing mRNA tightly binds and traps a splicing factor, muscleblindlike protein 1, which is then unavailable for the splicing of pre-mRNA from several other genes, including the muscle-specific chloride channel protein 1 (CLCN1). Lack of this channel results in muscle hyperexcitability, which causes myotonia 75 . In a mouse model of myotonia, the injection of a 25-mer PMO-based compound complementary to the CUG repeat displaced bound muscleblind-like protein 1 from the repeat and dispersed RNA foci in the fibres of the treated muscle (FIG. 3d) . Moreover, this treatment restored the correct splicing of CLCN1 and other affected genes. Restoration of the correct splicing of CLCN1 mRNA rescued the production of the chloride channel protein and restored its transmembrane chloride ion conductance. As a result, myotonia of the treated muscle was markedly reduced 76 . Similar results were obtained by intramuscular injections of 21-mer 2′-OMe phosphorothioate oligonucleotides 77 . Interestingly, oligonucleotide treatment may not only halt the course of the disease but also prevent its onset. Direct injection of CAG-repeat-targeted LNA oligonucleotides into the muscle of the myotonic mouse suppressed further expansion of the repeat. This suggests that early oligonucleotide treatment may stabilize the repeats at subpathogenic lengths 78 . Targeting splicing, as described above, shows that the splicing machinery -in spite of or perhaps because of its complexity and plasticity -provides an amenable and remarkably broad platform for manipulation by oligonucleotides. The achievable effects include repair of splicing defects and restoration of protein function in SMA and β-thalassaemia, or repair of mRNA in which deletions affect protein translation in DMD. These approaches led to the generation of partially functional dystrophin protein in treated animal models and patients with DMD. The possibility that a novel, clinically useful protein can be generated by manipulation of alternative splicing is exemplified by Δ7TNFR2, which had anti-inflammatory effects in mice. Finally, blocking the binding of a splicing factor to an extended triplet repeat has pleiotropic effects because it restores the correct splicing and expression of several genes, thus ameliorating myotonic dystrophy, a disorder whose aetiology has only become understood in the past few years.
Antibacterials and antivirals.
In addition to inducing the production of functional proteins, RNA-blocking oligonucleotides can be used to downregulate the production of undesirable proteins via several mechanisms. These include: redirection of splicing to prevent protein production; blocking of protein translation (FIG. 1c) ; and the generation of an EGS, which guides the tRNAprocessing ribozyme RNase P to cleave EGS-targeted mRNA (FIG. 1d) . Several reports, highlighted below, have shown the effectiveness of these approaches as antibacterial and antiviral treatments.
Oligonucleotides are rarely tested as antibacterials, because the bacterial cell wall presents a formidable obstacle to the entry of the oligonucleotide into the cell. Surprisingly, the administration of very short, 11-mer PMOs to Escherichia coli-infected mice downregulated the expression of the acyl carrier protein, which is essential for E. coli lipid biosynthesis 79 . Further work demonstrated that oligomers with the same sequence that were either conjugated to a cell-penetrating peptide (that is, PPMOs) or contained positively charged subunits within the backbone (positively charged PMOs; also known as PMOplus) (FIG. 2) were even more effective. All mice treated with either chemistry survived, whereas all control mice died 12 hours post-infection. On a molar basis, PPMO was more effective than ampicillin, a smallmolecule antibiotic 80, 81 . PPMOs were also used to inhibit bacterial growth and the expression of specific genes in cultures of E. coli (Gram-negative) and Bacillus subtilis (Gram-positive) bacteria. A unique feature of this work 82 is that PPMOs acted as EGSs, which are short RNAs that are designed to bind to targeted mRNA and form a three-dimensional structure that somewhat resembles tRNA (FIG. 1d) . This structure is recognized in bacterial and eukaryotic cells by a tRNA-processing ribozyme, RNase P, which cleaves the EGS-bound mRNA at the first base pair of the duplex formed by the EGS and the targeted mRNA (reviewed in REF. 83) . Surprisingly, when mRNA was hybridized to an EGS with a PMO backbone that was chemically very different from that of RNA (FIG. 2) , the complex was still recognized and the mRNA was cleaved by RNase P. Indeed, treatment of chloramphenicol-resistant E. coli with a mixture of two PPMO-EGSs targeted to mRNA encoding chloramphenicol-resistance protein reduced bacterial survival by 99 .9% in the presence of the antibiotic compared with bacteria treated with chloramphenicol only 84 . This efficacy suggests that the PPMO-EGS approach may be effective against infections caused by antibiotic-resistant strains of bacteria.
A recent paper summarized the effects of PPMOs conjugated to a different basic peptide 84 . This peptide, which was derived from a protein from human T cells and had no biological activity on its own, was a remarkable facilitator of the transport of a covalently attached PMO into bacteria. The new conjugate is 10-to 100-fold more effective at killing a variety of bacteriaincluding E. coli, Staphylococcus aureus and Klebsiella pneumoniae -than the previously tested compounds. The new conjugate is also effective at reducing the survival of drug-resistant bacteria. If the PMO conjugates that have sequences targeted to eukaryotic mRNAs -and are designed to be recognized as an EGS by eukaryotic RNase P -are delivered to eukaryotic cells, the new agent might also be effective against eukaryotic gene targets such as viral RNAs 85 . The effective treatment of monkeys infected with Ebola or Marburg viruses using PMO-based compounds provides a striking example of the utility of RNA-blocking morpholino oligomers in inhibiting viral mRNA translation 86 . Ebola and Marburg viruses are deadly haemorrhagic viruses and in an outbreak they can kill the majority of infected individuals. The only countermeasure is quarantine and prevention of the spread of the virus.
The treatment of Ebola virus-infected (~1000-fold greater than the minimum lethal dose) Rhesus macaque monkeys with the PMOplus drug candidate AVI-6002 resulted in 60% survival at 15 days post-infection, and the treatment of Marburg virus-infected (~1000-fold greater than the minimum lethal dose) Cynomolgus macaque monkeys with the PMOplus drug candidate AVI-6003 resulted in 100% survival at 15 days postinfection. This level of survival has not been observed previously; on average, untreated monkeys survive no more than 10-11 days 86 (P. Iversen, personal communication). At 15 days post-infection, both viruses were undetectable in the bloodstream of treated animals. Furthermore, surviving monkeys were resistant to infection when re-challenged with the virus more than 60 days after initial treatment, suggesting that the animals were able to mount an effective immune response once the infection progression was slowed down (P. Iversen, personal communication). The first safety clinical trials (ClinicalTrials.gov identifiers: NCT01353027 and NCT01353040) for AVI-6002 and AVI-6003 have been initiated (see the AVI BioPharma website).
AVI-6002 and AVI-6003 each target two independent genes that are essential for viral survival. This same double-target approach was used against several other viruses, including the clinically important respiratory syncytial virus, herpes simplex virus 1 (REFS 87, 88) , the picornavirus family 89 and influenza viruses [90] [91] [92] . Oligomers were targeted to the AUG sites or the highly conserved terminal sequences of appropriate genes. This double-target design is anticipated to minimize the emergence of resistant mutant viruses 86 . The increasing prevalence of bacterial and viral outbreaks as well as drug-resistant strains of these organisms indicates that there is a need for the development of novel antibacterial and antiviral drugs. Oligonucleotides may be a rapidly deployable -albeit currently expensive -answer to this problem.
Outlook
The only two approved nucleic acid-based drugsfomivirsen 3 , which is an antisense oligonucleotide, and pegaptanib (Macugen; Pfizer/Eyetech Pharmaceuticals), which is an RNA aptamer 4 that has not been not discussed in this Review -have reached the market and both are delivered locally by intravitreal injection. It could be argued that oligonucleotide-based drugs cannot be effective systemically because these large polar molecules do not follow Lipinski's rules 93 : empirical rules stating that, among other characteristics, effective drugs invariably have molecular weights below 500 Da and are fairly soluble in both polar and nonpolar solvents. Although oligonucleotides clearly do not meet these criteria, in our opinion -which is supported by the results reviewed above -this field is on the verge of success. Novel chemistries that enhance the cellular uptake of oligonucleotides are especially promising. Likewise, the potential of RNA-based therapeutics to reach heretofore undruggable targets and affect untreatable diseases certainly warrants the efforts to turn these compounds into effective drugs.
A comparison with monoclonal antibodies is instructive. These molecules are as far from Lipinski's rules as are oligonucleotides yet they have now reached a worldwide market of over $40 billion and are used against serious chronic diseases such as cancer, multiple sclerosis and rheumatoid arthritis. Antigen-specific monoclonal antibodies were first produced in 1975 (REF. 94 ), and although a single monoclonal antibody was approved by the FDA in 1986 the majority reached the market about 10 years later 95 . We believe that oligonucleotideand RNA-based therapeutics have the potential to follow a similar or shorter timeline and reach a similar level of success.
